Citigroup Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $402
Benzinga Newsdesk 10 hours ago
Analyst RatingsNewsPrice Target
Citigroup analyst Yigal Nochomovitz maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $397 to $402.
Citigroup analyst Yigal Nochomovitz maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $397 to $402.